摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-chloro-1-((2-methyloxiran-2-yl)methyl)-4-nitro-1H-imidazole | 681490-88-0

中文名称
——
中文别名
——
英文名称
2-chloro-1-((2-methyloxiran-2-yl)methyl)-4-nitro-1H-imidazole
英文别名
2-chloro-1-[(2-methyloxiran-2-yl)methyl]-4-nitro-1H-imidazole;2-chloro-1-[(2-methylepoxypropan-2-yl)methyl]-4-nitroimidazole;2-chloro-1-(2-methyl-oxiranylmethyl)-4-nitro-1H-imidazole;2-chloro-1-(2-methyloxiran-2-ylmethyl)-4-nitroimidazole;2-chloro-1-[(2-methyloxiran-2-yl)methyl]-4-nitroimidazole
2-chloro-1-((2-methyloxiran-2-yl)methyl)-4-nitro-1H-imidazole化学式
CAS
681490-88-0
化学式
C7H8ClN3O3
mdl
——
分子量
217.612
InChiKey
SZMDGYNOADBVSR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    393.9±38.0 °C(Predicted)
  • 密度:
    1.68±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    14
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.57
  • 拓扑面积:
    76.2
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

点击查看最新优质反应信息

文献信息

  • Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-<i>b</i>][1,3]oxazoles for Neglected Tropical Diseases: Structure–Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis
    作者:Andrew M. Thompson、Patrick D. O’Connor、Adrian Blaser、Vanessa Yardley、Louis Maes、Suman Gupta、Delphine Launay、Denis Martin、Scott G. Franzblau、Baojie Wan、Yuehong Wang、Zhenkun Ma、William A. Denny
    DOI:10.1021/acs.jmedchem.5b01699
    日期:2016.3.24
    linking oxygen for nitrogen (or piperazine), biaryl extension, and replacement of phenyl rings by pyridine. Several less lipophilic analogues displayed improved aqueous solubility, particularly at low pH, although stability toward liver microsomes was highly variable. Upon evaluation in a mouse model of acute Leishmania donovani infection, one phenylpyridine derivative (37) stood out, providing efficacy
    6-硝基-2,3-二氢咪唑[2,1- b最初在临床试验用药前驱体前药(PA-824)的备用程序中研究了[] [1,3]恶唑衍生物的结核病。表型筛选针对动素体疾病的代表性实例出乎意料地导致了DNDI-VL-2098的鉴定为潜在的内脏利什曼病(VL)的同类药物候选者。然后进行了其他工作来描述其基本结构特征,目的是在不损害针对VL的活性的情况下提高其溶解度和安全性。尽管4-硝基咪唑部分是特别需要的,但对芳氧基侧链的一些修饰是很好的耐受性,例如,将连接的氧交换成氮(或哌嗪),联芳基延伸以及用吡啶取代苯环。几种较不亲脂的类似物显示出改善的水溶性,尽管对肝微粒体的稳定性变化很大,但特别是在低pH下。在评估小鼠急性模型后利什曼原虫多诺万尼感染中,一种苯基吡啶衍生物(37)脱颖而出,其功效超过了临床前的先导药物。
  • [EN] NITROIMIDAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS DE NITROIMIDAZOLE
    申请人:GE HEALTHCARE LTD
    公开号:WO2011151320A1
    公开(公告)日:2011-12-08
    The present invention provides novel compounds useful in the treatment and diagnosis of mycobacterial infections. Compounds of the present invention have enhanced biological properties as compared to the related known compounds. The present invention also provides a precursor compound useful in the synthesis of certain compounds of the invention, and a method to obtain these compounds using said precursor compound. Methods of treatment and diagnosis in which the compounds of the invention find use are also provided.
    本发明提供了在治疗和诊断分枝杆菌感染中有用的新化合物。与相关已知化合物相比,本发明的化合物具有增强的生物特性。本发明还提供了一种在合成本发明某些化合物时有用的前体化合物,以及使用该前体化合物获得这些化合物的方法。本发明还提供了利用本发明化合物的治疗和诊断方法。
  • [EN] 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS<br/>[FR] COMPOSES 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE POUR LE TRAITEMENT DE LA TUBERCULOSE
    申请人:OTSUKA PHARMA CO LTD
    公开号:WO2005042542A1
    公开(公告)日:2005-05-12
    The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: (1)in the above formula (1), R1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R1 and -(CH2)nR2 may form a spiro ring represented by the formula (30) below, together with the adjacent carbon atom (in the formula below, RRR represents a piperidyl group which may have substituents on the piperidine ring), (30)and R2 represents a benzothiazolyloxy group, quinolyloxy group, pyridyloxy group or the like. The present compound has an excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria.
    本发明提供了一种由以下一般式表示的2,3-二氢-6-硝基咪唑[2,1-b]噁唑化合物:(1)在上述式(1)中,R1代表氢原子或C1-C6烷基,n代表0至6的整数,R1和-(CH2)nR2可以与下面的式(30)一起形成一个螺环,与相邻的碳原子一起(在下面的式中,RRR代表可能在哌啶环上具有取代基的哌啶基),(30)和R2代表苯并噻唑氧基、喹啉氧基、吡啶氧基或类似物。该化合物对结核分枝杆菌、多药耐药结核分枝杆菌和非典型耐酸细菌具有出色的杀菌作用。
  • 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles
    申请人:Tsubouchi Hidetsugu
    公开号:US20060094767A1
    公开(公告)日:2006-05-04
    The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: wherein R 1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R 2 represents a group —OR 3 or the like, and R 3 represents a hydrogen atom, C1-C6 alkyl group or the like, or R 1 and —(CH 2 ) n R 2 may bind to each other together with carbon atoms adjacent thereto through nitrogen atoms so as to form a spiro ring represented by the general formula (H): wherein R 41 is hydrogen, C1-C6 alkyl group or the like. The present compound has an excellent bactericidal action against Mycobacterium tuberculosis , multi-drug-resistant Mycobacterium tuberculosis , and atypical acid-fast bacteria.
    本发明提供了一种2,3-二氢-6-硝基咪唑并[2,1-b]噁唑化合物,其通式如下:其中,R1代表氢原子或C1-C6烷基,n代表0到6的整数,R2代表—OR3或类似的基团,R3代表氢原子、C1-C6烷基或类似的基团,或者R1和—(CH2)nR2可以通过相邻的碳原子通过氮原子结合在一起形成一个螺环,其通式为(H):其中,R41为氢、C1-C6烷基或类似的基团。该化合物对结核分枝杆菌、多药耐药结核分枝杆菌和非典型酸性快速细菌具有优异的杀菌作用。
  • 1-substituted-4-nitroimidazole compound and process for producing the same
    申请人:Goto Fumitake
    公开号:US20060079697A1
    公开(公告)日:2006-04-13
    The present invention relates to a 1-substituted-4-nitroimidazole compound represented by the general formula (1) or a salt thereof, (wherein R is a hydrogen atom, a lower alkoxy group-substituted lower alkyl group, a phenyl-lower alkoxy group-substituted lower alkyl group, a cyano-substituted lower alkyl group, a phenyl-lower alkyl group which may have lower alkoxy groups as the substituents in the phenyl ring or a group of the formula —CH 2 R A ; X is a halogen atom or a group of the formula —S(O)n—R 1 ) and method for preparing the same. The compound of the formula (1) is a useful compound as an intermediate for synthesis of various pharmaceutical and agricultural chemicals, particularly, as intermediates for antitubercular agents.
    本发明涉及一种1-取代-4-硝基咪唑化合物,其通式为(1),或其盐,其中R是氢原子,低烷氧基取代的低烷基,苯基-低烷氧基取代的低烷基,氰基取代的低烷基,苯基-低烷基(苯环上可能有低烷氧基取代物)或式子-CH2RA的基团;X是卤素原子或式子-S(O)n-R1的基团。本发明还涉及其制备方法。式(1)的化合物是一种有用的化合物,可用作合成各种药物和农药化学品的中间体,特别是抗结核药物的中间体。
查看更多

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺